Evidence map›Paper›PMID 33977579›Full record

ArticleMagnetic resonance in medicine2021

Spectral fitting strategy to overcome the overlap between 2-hydroxyglutarate and lipid resonances at 2.25 ppm.

Pegah Askari, Ivan E Dimitrov, Sandeep K Ganji, Vivek Tiwari, Michael Levy, Toral R Patel, Edward Pan, Bruce E Mickey, Craig R Malloy, Elizabeth A Maher and 1 more

Open access · greenAbstract read
In one paragraph

Article in Magnetic resonance in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Pitfalls in 2HG Detection With TE-Optimized MRS at 3T.Journal of neuroimaging : official journal of the American Society of Neuroimaging
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Pegah AskariAdvanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Ivan E DimitrovAdvanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Sandeep K GanjiPhilips Healthcare, Andover, Massachusetts, USA.
Vivek TiwariAdvanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Michael LevyDepartment of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Toral R PatelDepartment of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Edward PanDepartment of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Bruce E MickeyDepartment of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Craig R MalloyAdvanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0001-5077-0642
Elizabeth A MaherDepartment of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Changho ChoiAdvanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0002-7135-2447
Southwestern Medical Center · USCenter for Neuro-Oncology · USNeurological Surgery · USPhilips (United States) · USThe University of Texas at Arlington · USThe University of Texas Southwestern Medical Center · US

Funding

Understanding the role of IDH in malignant gliomasR01CA154843 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MAHER, ELIZABETH A · 2012 to 2022
$3.5M
Clinical development of cancer-specific MRS biomarkers in malignant gliomasR01CA184584 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI CHOI, CHANGHO · 2014 to 2018
$1.6M
Cancer Prevention and Research Institute of Texas RP200456NCI NIH HHS R01 CA154843NCI NIH HHS R01 CA184584NIH HHS R01CA184584
6 · The paper itself

Abstract

purpose

methodsTE 97 ms PRESS was acquired at 3T from 42 glioma patients. New lipid basis sets were created, in which the small lipid 2.25-ppm signal strength was preset with reference to the lipid signal at 0.9 ppm, incorporating published fat relaxation data. LCModel fitting using the new lipid bases (Fitting method 2) was conducted along with fitting using the LCModel built-in lipid basis set (Fitting method 1), in which the lipid 2.25-ppm signal is assessed with reference to the lipid 1.3-ppm signal. In-house basis spectra of low-molecular-weight metabolites were used in both fitting methods.

resultsFitting method 2 showed marked improvement in identifying IDH mutational status compared with Fitting method 1. 2HG estimates from Fitting method 2 were overall smaller than those from Fitting method 1, which was because of differential assignment of the signal at 2.25 ppm to lipids. In receiver operating characteristic analysis, Fitting method 2 provided a complete distinction between IDH mutation and wild-type whereas Fitting method 1 did not.

conclusionThe data suggest that

Indexed as

Brain NeoplasmsGliomaGlutaratesHumansLipidsMagnetic Resonance Spectroscopyalpha-hydroxyglutarateGlutaratesLipids1H MRS2HG2-Hydroxyglutarate3TIDH mutationLiplipidsTE 97 ms PRESS

Identifiers

PMID33977579
PMCPMC8295210
OpenAlexW3162838814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.